Why Choose Dexcom for Patient Care

Patient Benefits of CGM

Whether type 1 or type 2, injections or pump—your patient may benefit.

You are here

Who Can Benefit?

Many of your patients struggle to maintain good glycemic control, despite their best intentions. The barriers to good glycemic control are wide-ranging and far-reaching, contributing not only to long-term complications but also hindering a patient's day-to-day quality of life. 

CGM could be the right choice for these patients:

  • Type 1 and type 2 diabetes
  • Multiple daily injections (MDI) and insulin pump regimens
  • Not at A1C goal
  • Hypoglycemia unawareness
  • Problematic hypoglycemia
  • Wide fluctuations in glycemic variability
  • Unwilling or unable to carb count
  • Frustrated with fingersticks

More Insight than Monitoring Alone

Unlike a single reading from a blood glucose meter, continuous glucose monitoring (CGM) provides dynamic information about the speed and direction of glucose levels, giving your patient continuous and timely feedback on diet, exercise, and insulin requirements to help make informed diabetes treatment decisions. CGM is a powerful therapy management tool that can inform better diabetes treatment decisions, ultimately leading to tighter glycemic control than using a blood glucose meter alone.1 In fact real-time CGM use has been proven to improve glycemic variability and control across 29 indices, including2:

  • Percentage within control
  • Percentage above target
  • Percentage below target
  • Mean glucose
  • Standard deviation of daily means



Dispelling the Myths of CGM Usage in MDI Patients

There are commonly held beliefs in the diabetes community that patients on a multiple daily injections (MDI) regimen wouldn't benefit from CGM use either because they wouldn't be willing to wear a CGM device or they would find it too complicated to use. The Diamond study provides compelling evidence to challenge these misperceptions, showing that MDI patients experience significant A1C reductions, regardless of education level, math ability or age.3


CGM is too complicated to use, especially for populations with less education and math ability, and for those who are older. 


Study participants demonstrated significant A1C reductions, regardless of education level, math ability and age. 


MDI patients would be reluctant to use a wearable diabetes technology.


Subjects on a MDI insulin regimen demonstrated a high rate of adherence: at week 24, 93% of subjects were still using the Dexcom CGM System ≥6 days/week.



Take a Closer Look at Two Hypothetical Patient Profiles

Insulin Carb Ratio and Correction Factor Dosing Regimen

MDI Therapy

32-year-old with type 1 diabetes; current A1C of 7.8%.

Fixed Prandial Insulin Dosing Regimen

MDI Therapy

47-year-old with type 2 diabetes; current A1C is 9.2%; non-compliant with morning insulin injections.


Pettus J, Price DA, Edelman SV. How Patients with Type 1 Diabetes Translate Continuous Glucose Monitoring Data into Diabetes Management Decisions. Endocr Pract. 2015;:1-25.


Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009 Nov;11(11).727-23.


Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA. 2017; 317(4); 371-378.

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.